MedTrace Logo

The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients

NCT07244770 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-01-30

No results posted yet for this study

Summary

The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.

Conditions

Interventions

DRUG

SGLT2 Is+METFORMIN

Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months

DRUG

DPP4 Is+metformin

Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months

DRUG

Control group

patients administered their standard of care without any changes for the past 6 months

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-06-01
Completion
2026-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244770 on ClinicalTrials.gov